Abstract
We investigated the concentration of tacrolimus in aqueous humor, and serum of patients with ocular Behçet’s disease after topical application in 11 patients. All received 1 drop of isotonic tacrolimus solution 0.3% every 6 hours for 3 days. The mean tacrolimus concentration in the aqueous and serum, as measured by microparticle enzyme immunoassay, were 12.49 and 0.76 ng/mL, respectively. Tacrolimus may be a promising treatment modality in anterior uveitis in Behçet’s disease by topical application.
Similar content being viewed by others
References
Kino T, Hatanaka H, Hashimoto H, et al. FK-506, a novel immunosuppresant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot 1987; 40:1249–1255.
Kino T, Hatanaka H, Miyata S, et al. FK-506, a novel immunosuppresant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot 1987;40:1256–1265.
Sawada S, Suzuki G, Kawase Y, et al. Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation. J Immunol 1987;139:1797–1803.
Whitcup SM, Pleyer U, Lai JC, et al. Topical liposome-encapsulated FK506 for the treatment of endotoxin-induced uveitis. Ocul Immunol Inflamm 1998;6:51–56.
Kawashima H, Fujino Y, Mochizuki M. Effects of a new immunosuppressive agent, FK506, on experimental autoimmune uveoretinitis in rats. Invest Ophthalmol Vis Sci 1988;29:1265–1271.
Hikita N, Chan CC, Whitcup SM, et al. Effects of topical FK506 on endotoxin-induced uveitis (EIU) in the Lewis rat. Curr Eye Res 1995;14:209–214.
Sloper CM, Powell RJ, Dua HS. Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology 1999;106:723–728.
Kilmartin DJ, Forrester JV, Dick AD. Tacrolimus (FK506) in failed cyclosporin A therapy in endogenous posterior uveitis. Ocular Immunol and Inflamm 1998;6:101–109.
Mochizuki M, Masuda K, Sakane T, et al. A multicenter clinical open trial of FK506 in refractory uveitis, including Behcet’s disease. Transplant Proc 1991;23:3343–3346.
Ishioka M, Ohno S, Nakamura S, et al. FK506 treatment of noninfectious uveitis. Am J Ophthalmol 1994;118:723–729.
Pirsch JD, Miller J, Deierhoi MH, et al. A comparison of tacrolimus (FK506) and cyclosporin for immunosuppression after cadaveric renal transplantation. Transplantation 1997;63:977–983.
Pleyer U, Lutz S, Jusko WJ, et al. Ocular absorption of topically applied FK506 from liposomal and oil formulations in the rabbit eye. Invest Ophthalmol Vis Sci 1993;34:2737–2742.
Mills RA, Jones DB, Winkler CR, et al. Topical FK-506 prevents experimental corneal allograft rejection. Cornea 1995; 14:157–160.
Okada K, Sakata H, Minamoto A, et al. Effect of FK506 administered topically versus intramuscularly on suppression of the corneal immune reaction in rats. Ophthalmologica 1996;210: 175–179.
Hikita N, Lopez JS, Chan CC, Mochizuki M, et al. Use of topical FK506 in a corneal graft rejection model in Lewis rats. Invest Ophthalmol Vis Sci 1997;38:901–909.
Fitzgerald P, Hadgraft J, Wilson CG. A gamma-scintigraphic evaluation of microparticulate ophthalmic delivery systems: liposomes and nanoparticles. Int J Pharm 1987;40:81–88.
Author information
Authors and Affiliations
Corresponding author
Additional information
The authors have stated that they do not have a significant financial interest or other relationship with any product manufacturer or provider of services discussed in this article. The authors also do not discuss the use of off-label products, which includes unlabeled, unapproved, or investigative products or devices.
Rights and permissions
About this article
Cite this article
Yalçindaĝ, F.N., Batioĝlu, F. & Özdemir, Ö. Penetration of topically applied tacrolimus into the aqueous humor in Behçet’s disease. Ann Ophthalmol 39, 15–17 (2007). https://doi.org/10.1007/BF02697321
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02697321